{
  "company_id": "jnj",
  "company_name": "Johnson & Johnson",
  "generated_at": "2026-02-07T05:25:55Z",
  "kpis": {
    "assets_total": 17,
    "assets_with_trials": 5,
    "trials_total": 41
  },
  "top_assets": [
    {
      "asset_id": 3,
      "asset_name": "Azacitidine",
      "highest_stage": "Registration",
      "linked_trials_count": 4,
      "indications": [
        {
          "indication": "Cancer (ATLAS) intravesical delivery system) Invasive Bladder Cancer BCG (ORIGAMI-2) Multiple Myeloma CD38 exposed with DR (MajesTEC-7)",
          "stage": "Registration",
          "therapeutic_area": "Oncology"
        }
      ]
    },
    {
      "asset_id": 1,
      "asset_name": "RYBREVANT",
      "highest_stage": "Phase 3",
      "linked_trials_count": 27,
      "indications": [
        {
          "indication": "Frontline Non Small chemotherapy (PAPILLON) Bleximenib Newly Diagnosed AML, with Venetoclax and ERLEADA (apalutamide) ASCT Localized Prostate",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        }
      ]
    },
    {
      "asset_id": 2,
      "asset_name": "INLEXZO",
      "highest_stage": "Phase 3",
      "linked_trials_count": 5,
      "indications": [
        {
          "indication": "High Risk High Risk Non Muscle Experienced (SunRISe-5) RYBREVANT (amivantamab) Colorectal Cancer TALVEY + TECVAYLI Relapsed Refractory (MonumenTAL-6) TALVEY (talquetamab) TIE NDMM in combination",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        }
      ]
    },
    {
      "asset_id": 13,
      "asset_name": "JNJ-7446",
      "highest_stage": "Phase 3",
      "linked_trials_count": 2,
      "indications": [
        {
          "indication": "Lung Cancer",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        }
      ]
    },
    {
      "asset_id": 14,
      "asset_name": "JNJ-8543",
      "highest_stage": "Phase 3",
      "linked_trials_count": 0,
      "indications": [
        {
          "indication": "Hematological Malignancies",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        }
      ]
    },
    {
      "asset_id": 15,
      "asset_name": "JNJ-4804 Co-antibody",
      "highest_stage": "Phase 3",
      "linked_trials_count": 0,
      "indications": [
        {
          "indication": "Psoriatic Arthritis nipocalimab\u200b Systemic Lupus",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Crohn's Disease nipocalimab\u200b Idiopathic Inflammatory",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        }
      ]
    },
    {
      "asset_id": 12,
      "asset_name": "JNJ-4681",
      "highest_stage": "Phase 3",
      "linked_trials_count": 0,
      "indications": [
        {
          "indication": "Hematological Malignancies",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        }
      ]
    },
    {
      "asset_id": 11,
      "asset_name": "JNJ-3413",
      "highest_stage": "Phase 3",
      "linked_trials_count": 0,
      "indications": [
        {
          "indication": "Lymphoma",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        }
      ]
    },
    {
      "asset_id": 10,
      "asset_name": "JNJ-2175",
      "highest_stage": "Phase 3",
      "linked_trials_count": 0,
      "indications": [
        {
          "indication": "Solid Tumors",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        }
      ]
    },
    {
      "asset_id": 17,
      "asset_name": "JNJ-1887 sCD59",
      "highest_stage": "Phase 3",
      "linked_trials_count": 0,
      "indications": [
        {
          "indication": "Geographic Atrophy SPRAVATO (esketamine) Major Depressive Disorder Pediatrics",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience"
        }
      ]
    },
    {
      "asset_id": 4,
      "asset_name": "JNJ-1900",
      "highest_stage": "Phase 1",
      "linked_trials_count": 2,
      "indications": [
        {
          "indication": "Lung Cancer",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology"
        }
      ]
    },
    {
      "asset_id": 9,
      "asset_name": "JNJ-8377",
      "highest_stage": "Phase 1",
      "linked_trials_count": 0,
      "indications": [
        {
          "indication": "Lymphoma",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology"
        }
      ]
    },
    {
      "asset_id": 8,
      "asset_name": "JNJ-5322",
      "highest_stage": "Phase 1",
      "linked_trials_count": 0,
      "indications": [
        {
          "indication": "Multiple Myeloma",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology"
        }
      ]
    },
    {
      "asset_id": 16,
      "asset_name": "JNJ-5120",
      "highest_stage": "Phase 1",
      "linked_trials_count": 0,
      "indications": [
        {
          "indication": "Major Depressive",
          "stage": "Phase 1",
          "therapeutic_area": "Neuroscience"
        }
      ]
    },
    {
      "asset_id": 7,
      "asset_name": "JNJ-4680",
      "highest_stage": "Phase 1",
      "linked_trials_count": 0,
      "indications": [
        {
          "indication": "Lung Cancer",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology"
        }
      ]
    },
    {
      "asset_id": 6,
      "asset_name": "JNJ-2761",
      "highest_stage": "Phase 1",
      "linked_trials_count": 0,
      "indications": [
        {
          "indication": "Multiple Myeloma",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology"
        }
      ]
    },
    {
      "asset_id": 5,
      "asset_name": "JNJ-1493",
      "highest_stage": "Phase 1",
      "linked_trials_count": 0,
      "indications": [
        {
          "indication": "Hematological",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology"
        }
      ]
    }
  ],
  "recent_changes": [
    {
      "event_type": "trials_ingested",
      "created_at": "2026-02-07 05:25:52.512923",
      "occurred_at": "2026-02-07 05:25:52.512923",
      "payload": {
        "trials_seen": 41,
        "inserted": 41,
        "updated": 0,
        "status_changed": 0,
        "bad_aliases": 0
      }
    },
    {
      "event_type": "trial_alias_bootstrapped",
      "created_at": "2026-02-07 05:25:50.136606",
      "occurred_at": "2026-02-07 05:25:50.136606",
      "payload": {
        "query_alias": "Azacitidine",
        "added_alias": "ARGX-110",
        "assets": [
          3
        ]
      }
    },
    {
      "event_type": "trial_alias_bootstrapped",
      "created_at": "2026-02-07 05:25:50.133154",
      "occurred_at": "2026-02-07 05:25:50.133154",
      "payload": {
        "query_alias": "Azacitidine",
        "added_alias": "JNJ-74494550",
        "assets": [
          3
        ]
      }
    },
    {
      "event_type": "trial_alias_bootstrapped",
      "created_at": "2026-02-07 05:25:50.129829",
      "occurred_at": "2026-02-07 05:25:50.129829",
      "payload": {
        "query_alias": "Azacitidine",
        "added_alias": "Cusatuzumab",
        "assets": [
          3
        ]
      }
    },
    {
      "event_type": "trial_alias_bootstrapped",
      "created_at": "2026-02-07 05:25:50.125888",
      "occurred_at": "2026-02-07 05:25:50.125888",
      "payload": {
        "query_alias": "Azacitidine",
        "added_alias": "JNJ-75276617",
        "assets": [
          3
        ]
      }
    },
    {
      "event_type": "trial_alias_bootstrapped",
      "created_at": "2026-02-07 05:25:50.122183",
      "occurred_at": "2026-02-07 05:25:50.122183",
      "payload": {
        "query_alias": "Azacitidine",
        "added_alias": "Bleximenib",
        "assets": [
          3
        ]
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-07 05:25:48.942894",
      "occurred_at": "2026-02-07 05:25:48.942894",
      "payload": {
        "nct_id": "NCT04150887",
        "linked_assets": 2
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-07 05:25:48.933926",
      "occurred_at": "2026-02-07 05:25:48.933926",
      "payload": {
        "nct_id": "NCT04150887",
        "title": "An Open-label, Multicenter, Phase 1b Study of OV-1001 (Cusatuzumab; Anti-CD70 Monoclonal Antibody) in Combination With Background Therapy for the Treatment of Subjects With Acute Myeloid Leukemia"
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-07 05:25:48.425789",
      "occurred_at": "2026-02-07 05:25:48.425789",
      "payload": {
        "nct_id": "NCT04023526",
        "linked_assets": 2
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-07 05:25:48.415743",
      "occurred_at": "2026-02-07 05:25:48.415743",
      "payload": {
        "nct_id": "NCT04023526",
        "title": "A Phase 2 Study of Cusatuzumab Plus Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy"
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-07 05:25:47.609546",
      "occurred_at": "2026-02-07 05:25:47.609546",
      "payload": {
        "nct_id": "NCT06852222",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-07 05:25:47.600669",
      "occurred_at": "2026-02-07 05:25:47.600669",
      "payload": {
        "nct_id": "NCT06852222",
        "title": "A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Study of Bleximenib, Venetoclax and Azacitidine for the Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2A Rearrangements or NPM1 Mutations Who Are Ineligible for Intensive Chemotherapy"
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-07 05:25:47.589396",
      "occurred_at": "2026-02-07 05:25:47.589396",
      "payload": {
        "nct_id": "NCT05453903",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-07 05:25:47.580008",
      "occurred_at": "2026-02-07 05:25:47.580008",
      "payload": {
        "nct_id": "NCT05453903",
        "title": "A Phase 1b Study of Bleximenib in Combination With AML-Directed Therapies for Participants With Acute Myeloid Leukemia Harboring KMT2A or NPM1 Alterations"
      }
    },
    {
      "event_type": "trial_alias_bootstrapped",
      "created_at": "2026-02-07 05:25:47.409670",
      "occurred_at": "2026-02-07 05:25:47.409670",
      "payload": {
        "query_alias": "gemcitabine",
        "added_alias": "JNJ-63723283",
        "assets": [
          2
        ]
      }
    },
    {
      "event_type": "trial_alias_bootstrapped",
      "created_at": "2026-02-07 05:25:47.405383",
      "occurred_at": "2026-02-07 05:25:47.405383",
      "payload": {
        "query_alias": "gemcitabine",
        "added_alias": "Cetrelimab",
        "assets": [
          2
        ]
      }
    },
    {
      "event_type": "trial_alias_bootstrapped",
      "created_at": "2026-02-07 05:25:47.402203",
      "occurred_at": "2026-02-07 05:25:47.402203",
      "payload": {
        "query_alias": "gemcitabine",
        "added_alias": "JNJ-17000139",
        "assets": [
          2
        ]
      }
    },
    {
      "event_type": "trial_alias_bootstrapped",
      "created_at": "2026-02-07 05:25:47.398757",
      "occurred_at": "2026-02-07 05:25:47.398757",
      "payload": {
        "query_alias": "gemcitabine",
        "added_alias": "TAR-200",
        "assets": [
          2
        ]
      }
    },
    {
      "event_type": "trial_alias_bootstrapped",
      "created_at": "2026-02-07 05:25:47.394990",
      "occurred_at": "2026-02-07 05:25:47.394990",
      "payload": {
        "query_alias": "gemcitabine",
        "added_alias": "JNJ-42756493",
        "assets": [
          2
        ]
      }
    },
    {
      "event_type": "trial_alias_bootstrapped",
      "created_at": "2026-02-07 05:25:47.391139",
      "occurred_at": "2026-02-07 05:25:47.391139",
      "payload": {
        "query_alias": "gemcitabine",
        "added_alias": "TAR-210",
        "assets": [
          2
        ]
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-07 05:25:43.057420",
      "occurred_at": "2026-02-07 05:25:43.057420",
      "payload": {
        "nct_id": "NCT02436707",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-07 05:25:43.047216",
      "occurred_at": "2026-02-07 05:25:43.047216",
      "payload": {
        "nct_id": "NCT02436707",
        "title": "A Multi-Stage Randomized Phase II Study of Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma"
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-07 05:25:43.040090",
      "occurred_at": "2026-02-07 05:25:43.040090",
      "payload": {
        "nct_id": "NCT04658862",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-07 05:25:43.030820",
      "occurred_at": "2026-02-07 05:25:43.030820",
      "payload": {
        "nct_id": "NCT04658862",
        "title": "A Phase 3, Multi-center, Randomized Study Evaluating Efficacy of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder Who Are Not Receiving Radical Cystectomy"
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-07 05:25:43.016460",
      "occurred_at": "2026-02-07 05:25:43.016460",
      "payload": {
        "nct_id": "NCT04640623",
        "title": "Phase 2b Clinical Study Evaluating Efficacy and Safety of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Gu\u00e9rin (BCG) Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy"
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-07 05:25:43.008200",
      "occurred_at": "2026-02-07 05:25:43.008200",
      "payload": {
        "nct_id": "NCT06919965",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-07 05:25:42.996071",
      "occurred_at": "2026-02-07 05:25:42.996071",
      "payload": {
        "nct_id": "NCT06919965",
        "title": "A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Investigator's Choice of Intravesical Chemotherapy in Participants With High-risk Non-muscle-invasive Bladder Cancer With Susceptible FGFR Alterations Who Had Received Intravesical Bacillus Calmette-Gu\u00e9rin (BCG)"
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-07 05:25:42.988391",
      "occurred_at": "2026-02-07 05:25:42.988391",
      "payload": {
        "nct_id": "NCT06211764",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-07 05:25:42.979722",
      "occurred_at": "2026-02-07 05:25:42.979722",
      "payload": {
        "nct_id": "NCT06211764",
        "title": "A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gu\u00e9rin (BCG) and Recurred With High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy"
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-07 05:25:42.489752",
      "occurred_at": "2026-02-07 05:25:42.489752",
      "payload": {
        "nct_id": "NCT06319820",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-07 05:25:42.481158",
      "occurred_at": "2026-02-07 05:25:42.481158",
      "payload": {
        "nct_id": "NCT06319820",
        "title": "A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations"
      }
    },
    {
      "event_type": "trial_alias_bootstrapped",
      "created_at": "2026-02-07 05:25:42.252411",
      "occurred_at": "2026-02-07 05:25:42.252411",
      "payload": {
        "query_alias": "amivantamab",
        "added_alias": "Cetuximab",
        "assets": [
          1
        ]
      }
    },
    {
      "event_type": "trial_alias_bootstrapped",
      "created_at": "2026-02-07 05:25:42.248998",
      "occurred_at": "2026-02-07 05:25:42.248998",
      "payload": {
        "query_alias": "amivantamab",
        "added_alias": "YH25448",
        "assets": [
          1
        ]
      }
    },
    {
      "event_type": "trial_alias_bootstrapped",
      "created_at": "2026-02-07 05:25:42.245582",
      "occurred_at": "2026-02-07 05:25:42.245582",
      "payload": {
        "query_alias": "amivantamab",
        "added_alias": "JNJ-61186372",
        "assets": [
          1
        ]
      }
    },
    {
      "event_type": "trial_alias_bootstrapped",
      "created_at": "2026-02-07 05:25:42.243703",
      "occurred_at": "2026-02-07 05:25:42.243703",
      "payload": {
        "query_alias": "amivantamab",
        "added_alias": "YH-25448",
        "assets": [
          1
        ]
      }
    },
    {
      "event_type": "trial_alias_bootstrapped",
      "created_at": "2026-02-07 05:25:42.240489",
      "occurred_at": "2026-02-07 05:25:42.240489",
      "payload": {
        "query_alias": "amivantamab",
        "added_alias": "JNJ-73841937",
        "assets": [
          1
        ]
      }
    },
    {
      "event_type": "trial_alias_bootstrapped",
      "created_at": "2026-02-07 05:25:42.236660",
      "occurred_at": "2026-02-07 05:25:42.236660",
      "payload": {
        "query_alias": "amivantamab",
        "added_alias": "Lazertinib",
        "assets": [
          1
        ]
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-07 05:25:41.931694",
      "occurred_at": "2026-02-07 05:25:41.931694",
      "payload": {
        "nct_id": "NCT03767075",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-07 05:25:41.923605",
      "occurred_at": "2026-02-07 05:25:41.923605",
      "payload": {
        "nct_id": "NCT03767075",
        "title": "Basket of Baskets: A Modular, Open-label, Phase II, Multicentre Study To Evaluate Targeted Agents in Molecularly Selected Populations With Advanced Solid Tumours"
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-07 05:25:41.915853",
      "occurred_at": "2026-02-07 05:25:41.915853",
      "payload": {
        "nct_id": "NCT06816992",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-07 05:25:41.907255",
      "occurred_at": "2026-02-07 05:25:41.907255",
      "payload": {
        "nct_id": "NCT06816992",
        "title": "Phase 1b Study of ORIC-114 in Combination with Amivantamab in Patients with EGFR Exon20 Insertion Mutant NSCLC"
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-07 05:25:41.900410",
      "occurred_at": "2026-02-07 05:25:41.900410",
      "payload": {
        "nct_id": "NCT06632236",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-07 05:25:41.892689",
      "occurred_at": "2026-02-07 05:25:41.892689",
      "payload": {
        "nct_id": "NCT06632236",
        "title": "5G-EMERALD: A Phase 1 Trial of Amivantamab in High Grade Malignant Brain Tumours Within the 5G Platform"
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-07 05:25:41.883628",
      "occurred_at": "2026-02-07 05:25:41.883628",
      "payload": {
        "nct_id": "NCT05117931",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-07 05:25:41.876292",
      "occurred_at": "2026-02-07 05:25:41.876292",
      "payload": {
        "nct_id": "NCT05117931",
        "title": "Phase II Study of Amivantamab in EGFR or MET- Amplified Esophagogastric Cancer"
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-07 05:25:41.869604",
      "occurred_at": "2026-02-07 05:25:41.869604",
      "payload": {
        "nct_id": "NCT05299125",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-07 05:25:41.861513",
      "occurred_at": "2026-02-07 05:25:41.861513",
      "payload": {
        "nct_id": "NCT05299125",
        "title": "A Single Arm, Phase 2 Study of Amivantamab, Lazertinib and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers (NSCLCs) With EGFR Mutations"
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-07 05:25:41.854742",
      "occurred_at": "2026-02-07 05:25:41.854742",
      "payload": {
        "nct_id": "NCT04077463",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-07 05:25:41.845791",
      "occurred_at": "2026-02-07 05:25:41.845791",
      "payload": {
        "nct_id": "NCT04077463",
        "title": "An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ-73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non-Small Cell Lung Cancer"
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-07 05:25:41.833263",
      "occurred_at": "2026-02-07 05:25:41.833263",
      "payload": {
        "nct_id": "NCT04606381",
        "title": "An Open-label, Multicenter, Dose Escalation Phase 1b Study to Assess the Safety and Pharmacokinetics of Subcutaneous Delivery of Amivantamab, a Human Bispecific EGFR and cMet Antibody for the Treatment of Advanced Solid Malignancies"
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-07 05:25:41.826463",
      "occurred_at": "2026-02-07 05:25:41.826463",
      "payload": {
        "nct_id": "NCT05845671",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-07 05:25:41.818076",
      "occurred_at": "2026-02-07 05:25:41.818076",
      "payload": {
        "nct_id": "NCT05845671",
        "title": "A Phase 1 / 2, Open Label, Study of Amivantamab (JNJ-61186372) Among Participants With Advanced NSCLC Harboring ALK, ROS1, and RET Gene Fusions in Combination With Tyrosine Kinase Inhibitors"
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-07 05:25:41.811232",
      "occurred_at": "2026-02-07 05:25:41.811232",
      "payload": {
        "nct_id": "NCT05488314",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-07 05:25:41.803637",
      "occurred_at": "2026-02-07 05:25:41.803637",
      "payload": {
        "nct_id": "NCT05488314",
        "title": "A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer"
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-07 05:25:41.796191",
      "occurred_at": "2026-02-07 05:25:41.796191",
      "payload": {
        "nct_id": "NCT06662786",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-07 05:25:41.787473",
      "occurred_at": "2026-02-07 05:25:41.787473",
      "payload": {
        "nct_id": "NCT06662786",
        "title": "A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer"
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-07 05:25:41.770766",
      "occurred_at": "2026-02-07 05:25:41.770766",
      "payload": {
        "nct_id": "NCT05498428",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-07 05:25:41.762160",
      "occurred_at": "2026-02-07 05:25:41.762160",
      "payload": {
        "nct_id": "NCT05498428",
        "title": "A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients With Advanced or Metastatic Solid Tumors Including EGFR-mutated Non-Small Cell Lung Cancer"
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-07 05:25:41.749736",
      "occurred_at": "2026-02-07 05:25:41.749736",
      "payload": {
        "nct_id": "NCT07230691",
        "title": "Prospective, Multi Country, Observational Study of Clinical Outcomes in EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated With Approved Amivantamab-containing Regimens Under Standard Clinical Practice"
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-07 05:25:41.743091",
      "occurred_at": "2026-02-07 05:25:41.743091",
      "payload": {
        "nct_id": "NCT06532032",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-07 05:25:41.734290",
      "occurred_at": "2026-02-07 05:25:41.734290",
      "payload": {
        "nct_id": "NCT06532032",
        "title": "A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Docetaxel Combination Therapy in Metastatic Non-small Cell Lung Cancer"
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-07 05:25:41.727609",
      "occurred_at": "2026-02-07 05:25:41.727609",
      "payload": {
        "nct_id": "NCT02609776",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-07 05:25:41.719300",
      "occurred_at": "2026-02-07 05:25:41.719300",
      "payload": {
        "nct_id": "NCT02609776",
        "title": "A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects With Advanced Non-Small Cell Lung Cancer"
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-07 05:25:41.712064",
      "occurred_at": "2026-02-07 05:25:41.712064",
      "payload": {
        "nct_id": "NCT06385080",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-07 05:25:41.703311",
      "occurred_at": "2026-02-07 05:25:41.703311",
      "payload": {
        "nct_id": "NCT06385080",
        "title": "A Phase 1b/2, Open-label Study of Amivantamab Monotherapy and Amivantamab in Addition to Other Therapeutic Agents in Participants With Head and Neck Squamous Cell Carcinoma"
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-07 05:25:41.696038",
      "occurred_at": "2026-02-07 05:25:41.696038",
      "payload": {
        "nct_id": "NCT05908734",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-07 05:25:41.687867",
      "occurred_at": "2026-02-07 05:25:41.687867",
      "payload": {
        "nct_id": "NCT05908734",
        "title": "A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Cetrelimab Combination Therapy in Metastatic Non-small Cell Lung Cancer"
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-07 05:25:41.680685",
      "occurred_at": "2026-02-07 05:25:41.680685",
      "payload": {
        "nct_id": "NCT06750094",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-07 05:25:41.671492",
      "occurred_at": "2026-02-07 05:25:41.671492",
      "payload": {
        "nct_id": "NCT06750094",
        "title": "A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Recurrent, Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy"
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-07 05:25:41.659628",
      "occurred_at": "2026-02-07 05:25:41.659628",
      "payload": {
        "nct_id": "NCT06120140",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-07 05:25:41.650068",
      "occurred_at": "2026-02-07 05:25:41.650068",
      "payload": {
        "nct_id": "NCT06120140",
        "title": "A Phase 2, Open-Label, Randomized Trial Evaluating the Impact of Enhanced Versus Standard Dermatologic Management on Selected Dermatologic Adverse Events Among Patients With Locally Advanced or Metastatic EGFR-Mutated NSCLC Treated First-Line With Amivantamab + Lazertinib"
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-07 05:25:41.641231",
      "occurred_at": "2026-02-07 05:25:41.641231",
      "payload": {
        "nct_id": "NCT06667076",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-07 05:25:41.633000",
      "occurred_at": "2026-02-07 05:25:41.633000",
      "payload": {
        "nct_id": "NCT06667076",
        "title": "A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination With Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination With Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer"
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-07 05:25:41.624258",
      "occurred_at": "2026-02-07 05:25:41.624258",
      "payload": {
        "nct_id": "NCT05601973",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-07 05:25:41.616840",
      "occurred_at": "2026-02-07 05:25:41.616840",
      "payload": {
        "nct_id": "NCT05601973",
        "title": "A Multicentre Single-arm Phase II Trial of Amivantamab, Lazertinib Plus Bevacizumab in Patients With EGFR-mutant Advanced NSCLC With Progression on Previous Third-generation EGFR-TKI"
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-07 05:25:41.610096",
      "occurred_at": "2026-02-07 05:25:41.610096",
      "payload": {
        "nct_id": "NCT05388669",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-07 05:25:41.601709",
      "occurred_at": "2026-02-07 05:25:41.601709",
      "payload": {
        "nct_id": "NCT05388669",
        "title": "A Phase 3, Open-label, Randomized Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Patients With EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer After Progression on Osimertinib and Chemotherapy"
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-07 05:25:41.588254",
      "occurred_at": "2026-02-07 05:25:41.588254",
      "payload": {
        "nct_id": "NCT04487080",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-07 05:25:41.554470",
      "occurred_at": "2026-02-07 05:25:41.554470",
      "payload": {
        "nct_id": "NCT04487080",
        "title": "A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer."
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-07 05:25:41.535020",
      "occurred_at": "2026-02-07 05:25:41.535020",
      "payload": {
        "nct_id": "NCT05663866",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-07 05:25:41.526624",
      "occurred_at": "2026-02-07 05:25:41.526624",
      "payload": {
        "nct_id": "NCT05663866",
        "title": "Subcutaneous Methotrexate, Oral Dexamethasone or Oral Montelukast for the Prevention of Infusion Related Reaction Associated With Amivantamab, an EGFR-MET Bispecific Antibody, Among Post-osimertinib Treated EGFRm NSCLC; SKIPPirr, a Phase 2 Study"
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-07 05:25:41.514389",
      "occurred_at": "2026-02-07 05:25:41.514389",
      "payload": {
        "nct_id": "NCT04538664",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-07 05:25:41.506216",
      "occurred_at": "2026-02-07 05:25:41.506216",
      "payload": {
        "nct_id": "NCT04538664",
        "title": "A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Patients With EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer"
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-07 05:25:41.492129",
      "occurred_at": "2026-02-07 05:25:41.492129",
      "payload": {
        "nct_id": "NCT04988295",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-07 05:25:41.483603",
      "occurred_at": "2026-02-07 05:25:41.483603",
      "payload": {
        "nct_id": "NCT04988295",
        "title": "A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure"
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-07 05:25:41.467060",
      "occurred_at": "2026-02-07 05:25:41.467060",
      "payload": {
        "nct_id": "NCT07062354",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-07 05:25:41.458255",
      "occurred_at": "2026-02-07 05:25:41.458255",
      "payload": {
        "nct_id": "NCT07062354",
        "title": "A Phase II Study of Combined Amivantamab, Carboplatin and Paclitaxel in Unresectable Locally Recurrent or Metastatic Head and Neck Cancer"
      }
    },
    {
      "event_type": "trial_alias_bootstrapped",
      "created_at": "2026-02-07 05:25:41.313037",
      "occurred_at": "2026-02-07 05:25:41.313037",
      "payload": {
        "query_alias": "RYBREVANT",
        "added_alias": "JNJ-61186372",
        "assets": [
          1
        ]
      }
    },
    {
      "event_type": "trial_alias_bootstrapped",
      "created_at": "2026-02-07 05:25:41.307043",
      "occurred_at": "2026-02-07 05:25:41.307043",
      "payload": {
        "query_alias": "RYBREVANT",
        "added_alias": "Amivantamab",
        "assets": [
          1
        ]
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-07 05:25:41.004132",
      "occurred_at": "2026-02-07 05:25:41.004132",
      "payload": {
        "nct_id": "NCT07276399",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-07 05:25:40.995926",
      "occurred_at": "2026-02-07 05:25:40.995926",
      "payload": {
        "nct_id": "NCT07276399",
        "title": "A Phase 3, Randomized, Open-Label, Multicenter Study of Amivantamab in Addition to Carboplatin and Pembrolizumab, Compared to Standard of Care Platinum and Pembrolizumab and 5-FU, in Participants With Treatment-Na\u00efve Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma"
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-07 05:25:40.987670",
      "occurred_at": "2026-02-07 05:25:40.987670",
      "payload": {
        "nct_id": "NCT07227025",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-07 05:25:40.979668",
      "occurred_at": "2026-02-07 05:25:40.979668",
      "payload": {
        "nct_id": "NCT07227025",
        "title": "A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Olomorasib Combination Therapy in Metastatic Non-small Cell Lung Cancer"
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-07 05:25:40.971931",
      "occurred_at": "2026-02-07 05:25:40.971931",
      "payload": {
        "nct_id": "NCT05379595",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-07 05:25:40.963048",
      "occurred_at": "2026-02-07 05:25:40.963048",
      "payload": {
        "nct_id": "NCT05379595",
        "title": "A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer"
      }
    },
    {
      "event_type": "trial_alias_bootstrapped",
      "created_at": "2026-02-07 05:25:35.238539",
      "occurred_at": "2026-02-07 05:25:35.238539",
      "payload": {
        "query_alias": "NBTXR3",
        "added_alias": "JNJ-90301900",
        "assets": [
          4
        ]
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-07 05:25:34.932181",
      "occurred_at": "2026-02-07 05:25:34.932181",
      "payload": {
        "nct_id": "NCT07219212",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-07 05:25:34.922735",
      "occurred_at": "2026-02-07 05:25:34.922735",
      "payload": {
        "nct_id": "NCT07219212",
        "title": "A Study of JNJ-90301900 in Combination With Concurrent Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma"
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-07 05:25:34.915361",
      "occurred_at": "2026-02-07 05:25:34.915361",
      "payload": {
        "nct_id": "NCT04892173",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-07 05:25:34.900569",
      "occurred_at": "2026-02-07 05:25:34.900569",
      "payload": {
        "nct_id": "NCT04892173",
        "title": "A Phase 3 Study of NBTXR3 Activated by Investigator's Choice of Radiotherapy Alone or Radiotherapy in Combination With Cetuximab for Platinum-based Chemotherapy-Ineligible Elderly Patients With LA-HNSCC"
      }
    },
    {
      "event_type": "pipeline_ingested",
      "created_at": "2026-02-07 05:25:31.353766",
      "occurred_at": "2026-02-07 05:25:31.353766",
      "payload": {
        "as_of_date": null,
        "pdf_url": "https://s203.q4cdn.com/636242992/files/doc_financials/2025/q4/JNJ-Pipeline-4Q25.pdf",
        "assets_seen": 18
      }
    },
    {
      "event_type": "asset_indication_added",
      "created_at": "2026-02-07 05:25:31.349736",
      "occurred_at": "2026-02-07 05:25:31.349736",
      "payload": {
        "asset": "JNJ-1887 sCD59",
        "indication": "Geographic Atrophy SPRAVATO (esketamine) Major Depressive Disorder Pediatrics",
        "stage": "Phase 3",
        "therapeutic_area": "Neuroscience"
      }
    },
    {
      "event_type": "asset_indication_added",
      "created_at": "2026-02-07 05:25:31.340635",
      "occurred_at": "2026-02-07 05:25:31.340635",
      "payload": {
        "asset": "JNJ-5120",
        "indication": "Major Depressive",
        "stage": "Phase 1",
        "therapeutic_area": "Neuroscience"
      }
    },
    {
      "event_type": "asset_indication_added",
      "created_at": "2026-02-07 05:25:31.331553",
      "occurred_at": "2026-02-07 05:25:31.331553",
      "payload": {
        "asset": "JNJ-4804 Co-antibody",
        "indication": "Crohn's Disease nipocalimab\u200b Idiopathic Inflammatory",
        "stage": "Phase 3",
        "therapeutic_area": "Immunology"
      }
    },
    {
      "event_type": "asset_indication_added",
      "created_at": "2026-02-07 05:25:31.329201",
      "occurred_at": "2026-02-07 05:25:31.329201",
      "payload": {
        "asset": "JNJ-4804 Co-antibody",
        "indication": "Psoriatic Arthritis nipocalimab\u200b Systemic Lupus",
        "stage": "Phase 1",
        "therapeutic_area": "Immunology"
      }
    },
    {
      "event_type": "asset_indication_added",
      "created_at": "2026-02-07 05:25:31.319017",
      "occurred_at": "2026-02-07 05:25:31.319017",
      "payload": {
        "asset": "JNJ-8543",
        "indication": "Hematological Malignancies",
        "stage": "Phase 3",
        "therapeutic_area": "Oncology"
      }
    },
    {
      "event_type": "asset_indication_added",
      "created_at": "2026-02-07 05:25:31.309758",
      "occurred_at": "2026-02-07 05:25:31.309758",
      "payload": {
        "asset": "JNJ-7446",
        "indication": "Lung Cancer",
        "stage": "Phase 3",
        "therapeutic_area": "Oncology"
      }
    },
    {
      "event_type": "asset_indication_added",
      "created_at": "2026-02-07 05:25:31.300356",
      "occurred_at": "2026-02-07 05:25:31.300356",
      "payload": {
        "asset": "JNJ-4681",
        "indication": "Hematological Malignancies",
        "stage": "Phase 3",
        "therapeutic_area": "Oncology"
      }
    },
    {
      "event_type": "asset_indication_added",
      "created_at": "2026-02-07 05:25:31.291053",
      "occurred_at": "2026-02-07 05:25:31.291053",
      "payload": {
        "asset": "JNJ-3413",
        "indication": "Lymphoma",
        "stage": "Phase 3",
        "therapeutic_area": "Oncology"
      }
    },
    {
      "event_type": "asset_indication_added",
      "created_at": "2026-02-07 05:25:31.281600",
      "occurred_at": "2026-02-07 05:25:31.281600",
      "payload": {
        "asset": "JNJ-2175",
        "indication": "Solid Tumors",
        "stage": "Phase 3",
        "therapeutic_area": "Oncology"
      }
    },
    {
      "event_type": "asset_indication_added",
      "created_at": "2026-02-07 05:25:31.271921",
      "occurred_at": "2026-02-07 05:25:31.271921",
      "payload": {
        "asset": "JNJ-8377",
        "indication": "Lymphoma",
        "stage": "Phase 1",
        "therapeutic_area": "Oncology"
      }
    },
    {
      "event_type": "asset_indication_added",
      "created_at": "2026-02-07 05:25:31.262702",
      "occurred_at": "2026-02-07 05:25:31.262702",
      "payload": {
        "asset": "JNJ-5322",
        "indication": "Multiple Myeloma",
        "stage": "Phase 1",
        "therapeutic_area": "Oncology"
      }
    },
    {
      "event_type": "asset_indication_added",
      "created_at": "2026-02-07 05:25:31.253521",
      "occurred_at": "2026-02-07 05:25:31.253521",
      "payload": {
        "asset": "JNJ-4680",
        "indication": "Lung Cancer",
        "stage": "Phase 1",
        "therapeutic_area": "Oncology"
      }
    },
    {
      "event_type": "asset_indication_added",
      "created_at": "2026-02-07 05:25:31.244620",
      "occurred_at": "2026-02-07 05:25:31.244620",
      "payload": {
        "asset": "JNJ-2761",
        "indication": "Multiple Myeloma",
        "stage": "Phase 1",
        "therapeutic_area": "Oncology"
      }
    },
    {
      "event_type": "asset_indication_added",
      "created_at": "2026-02-07 05:25:31.234315",
      "occurred_at": "2026-02-07 05:25:31.234315",
      "payload": {
        "asset": "JNJ-1493",
        "indication": "Hematological",
        "stage": "Phase 1",
        "therapeutic_area": "Oncology"
      }
    },
    {
      "event_type": "asset_indication_added",
      "created_at": "2026-02-07 05:25:31.223321",
      "occurred_at": "2026-02-07 05:25:31.223321",
      "payload": {
        "asset": "JNJ-1900",
        "indication": "Lung Cancer",
        "stage": "Phase 1",
        "therapeutic_area": "Oncology"
      }
    },
    {
      "event_type": "asset_indication_added",
      "created_at": "2026-02-07 05:25:31.209535",
      "occurred_at": "2026-02-07 05:25:31.209535",
      "payload": {
        "asset": "Azacitidine",
        "indication": "Cancer (ATLAS) intravesical delivery system) Invasive Bladder Cancer BCG (ORIGAMI-2) Multiple Myeloma CD38 exposed with DR (MajesTEC-7)",
        "stage": "Registration",
        "therapeutic_area": "Oncology"
      }
    },
    {
      "event_type": "asset_indication_added",
      "created_at": "2026-02-07 05:25:31.197564",
      "occurred_at": "2026-02-07 05:25:31.197564",
      "payload": {
        "asset": "INLEXZO",
        "indication": "High Risk High Risk Non Muscle Experienced (SunRISe-5) RYBREVANT (amivantamab) Colorectal Cancer TALVEY + TECVAYLI Relapsed Refractory (MonumenTAL-6) TALVEY (talquetamab) TIE NDMM in combination",
        "stage": "Phase 3",
        "therapeutic_area": "Oncology"
      }
    },
    {
      "event_type": "asset_indication_added",
      "created_at": "2026-02-07 05:25:31.180661",
      "occurred_at": "2026-02-07 05:25:31.180661",
      "payload": {
        "asset": "RYBREVANT",
        "indication": "Frontline Non Small chemotherapy (PAPILLON) Bleximenib Newly Diagnosed AML, with Venetoclax and ERLEADA (apalutamide) ASCT Localized Prostate",
        "stage": "Phase 3",
        "therapeutic_area": "Oncology"
      }
    }
  ],
  "trials": [
    {
      "nct_id": "NCT07062354",
      "overall_status": "NOT_YET_RECRUITING",
      "phase": "PHASE2",
      "last_update_posted": "2026-02-06",
      "linked_assets": [
        "RYBREVANT"
      ]
    },
    {
      "nct_id": "NCT04988295",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "last_update_posted": "2026-02-05",
      "linked_assets": [
        "RYBREVANT"
      ]
    },
    {
      "nct_id": "NCT04487080",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "last_update_posted": "2026-02-04",
      "linked_assets": [
        "RYBREVANT"
      ]
    },
    {
      "nct_id": "NCT05663866",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "last_update_posted": "2026-02-04",
      "linked_assets": [
        "RYBREVANT"
      ]
    },
    {
      "nct_id": "NCT04538664",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "last_update_posted": "2026-02-04",
      "linked_assets": [
        "RYBREVANT"
      ]
    },
    {
      "nct_id": "NCT05388669",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "last_update_posted": "2026-02-02",
      "linked_assets": [
        "RYBREVANT"
      ]
    },
    {
      "nct_id": "NCT06319820",
      "overall_status": "RECRUITING",
      "phase": "PHASE3",
      "last_update_posted": "2026-01-27",
      "linked_assets": [
        "INLEXZO"
      ]
    },
    {
      "nct_id": "NCT05601973",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "last_update_posted": "2026-01-21",
      "linked_assets": [
        "RYBREVANT"
      ]
    },
    {
      "nct_id": "NCT06852222",
      "overall_status": "RECRUITING",
      "phase": "PHASE3",
      "last_update_posted": "2026-01-16",
      "linked_assets": [
        "Azacitidine"
      ]
    },
    {
      "nct_id": "NCT05453903",
      "overall_status": "RECRUITING",
      "phase": "PHASE1",
      "last_update_posted": "2026-01-16",
      "linked_assets": [
        "Azacitidine"
      ]
    },
    {
      "nct_id": "NCT04658862",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "last_update_posted": "2026-01-16",
      "linked_assets": [
        "INLEXZO"
      ]
    },
    {
      "nct_id": "NCT04640623",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "last_update_posted": "2026-01-16",
      "linked_assets": []
    },
    {
      "nct_id": "NCT06919965",
      "overall_status": "RECRUITING",
      "phase": "PHASE3",
      "last_update_posted": "2026-01-16",
      "linked_assets": [
        "INLEXZO"
      ]
    },
    {
      "nct_id": "NCT06211764",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "last_update_posted": "2026-01-16",
      "linked_assets": [
        "INLEXZO"
      ]
    },
    {
      "nct_id": "NCT05488314",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE1,PHASE2",
      "last_update_posted": "2026-01-16",
      "linked_assets": [
        "RYBREVANT"
      ]
    },
    {
      "nct_id": "NCT06662786",
      "overall_status": "RECRUITING",
      "phase": "PHASE3",
      "last_update_posted": "2026-01-16",
      "linked_assets": [
        "RYBREVANT"
      ]
    },
    {
      "nct_id": "NCT05498428",
      "overall_status": "RECRUITING",
      "phase": "PHASE2",
      "last_update_posted": "2026-01-16",
      "linked_assets": [
        "RYBREVANT"
      ]
    },
    {
      "nct_id": "NCT07230691",
      "overall_status": "RECRUITING",
      "phase": null,
      "last_update_posted": "2026-01-16",
      "linked_assets": []
    },
    {
      "nct_id": "NCT06532032",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE1,PHASE2",
      "last_update_posted": "2026-01-16",
      "linked_assets": [
        "RYBREVANT"
      ]
    },
    {
      "nct_id": "NCT02609776",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE1",
      "last_update_posted": "2026-01-16",
      "linked_assets": [
        "RYBREVANT"
      ]
    },
    {
      "nct_id": "NCT06385080",
      "overall_status": "RECRUITING",
      "phase": "PHASE1,PHASE2",
      "last_update_posted": "2026-01-16",
      "linked_assets": [
        "RYBREVANT"
      ]
    },
    {
      "nct_id": "NCT05908734",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE1,PHASE2",
      "last_update_posted": "2026-01-16",
      "linked_assets": [
        "RYBREVANT"
      ]
    },
    {
      "nct_id": "NCT06750094",
      "overall_status": "RECRUITING",
      "phase": "PHASE3",
      "last_update_posted": "2026-01-16",
      "linked_assets": [
        "RYBREVANT"
      ]
    },
    {
      "nct_id": "NCT06120140",
      "overall_status": "RECRUITING",
      "phase": "PHASE2",
      "last_update_posted": "2026-01-16",
      "linked_assets": [
        "RYBREVANT"
      ]
    },
    {
      "nct_id": "NCT06667076",
      "overall_status": "RECRUITING",
      "phase": "PHASE2",
      "last_update_posted": "2026-01-16",
      "linked_assets": [
        "RYBREVANT"
      ]
    },
    {
      "nct_id": "NCT07227025",
      "overall_status": "RECRUITING",
      "phase": "PHASE1,PHASE2",
      "last_update_posted": "2026-01-16",
      "linked_assets": [
        "RYBREVANT"
      ]
    },
    {
      "nct_id": "NCT05379595",
      "overall_status": "RECRUITING",
      "phase": "PHASE1,PHASE2",
      "last_update_posted": "2026-01-16",
      "linked_assets": [
        "RYBREVANT"
      ]
    },
    {
      "nct_id": "NCT07219212",
      "overall_status": "RECRUITING",
      "phase": "PHASE1",
      "last_update_posted": "2026-01-16",
      "linked_assets": [
        "JNJ-1900"
      ]
    },
    {
      "nct_id": "NCT04892173",
      "overall_status": "RECRUITING",
      "phase": "PHASE3",
      "last_update_posted": "2026-01-16",
      "linked_assets": [
        "JNJ-1900"
      ]
    },
    {
      "nct_id": "NCT02436707",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "last_update_posted": "2026-01-14",
      "linked_assets": [
        "INLEXZO"
      ]
    },
    {
      "nct_id": "NCT05845671",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE1,PHASE2",
      "last_update_posted": "2026-01-14",
      "linked_assets": [
        "RYBREVANT"
      ]
    },
    {
      "nct_id": "NCT04606381",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE1",
      "last_update_posted": "2026-01-13",
      "linked_assets": []
    },
    {
      "nct_id": "NCT04077463",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE1",
      "last_update_posted": "2025-12-24",
      "linked_assets": [
        "RYBREVANT"
      ]
    },
    {
      "nct_id": "NCT07276399",
      "overall_status": "RECRUITING",
      "phase": "PHASE3",
      "last_update_posted": "2025-12-19",
      "linked_assets": [
        "RYBREVANT"
      ]
    },
    {
      "nct_id": "NCT05299125",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "last_update_posted": "2025-10-01",
      "linked_assets": [
        "RYBREVANT"
      ]
    },
    {
      "nct_id": "NCT04023526",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "last_update_posted": "2025-08-20",
      "linked_assets": [
        "Azacitidine",
        "JNJ-7446"
      ]
    },
    {
      "nct_id": "NCT05117931",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "last_update_posted": "2025-07-20",
      "linked_assets": [
        "RYBREVANT"
      ]
    },
    {
      "nct_id": "NCT06632236",
      "overall_status": "RECRUITING",
      "phase": "PHASE1",
      "last_update_posted": "2025-04-25",
      "linked_assets": [
        "RYBREVANT"
      ]
    },
    {
      "nct_id": "NCT04150887",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE1",
      "last_update_posted": "2025-04-17",
      "linked_assets": [
        "Azacitidine",
        "JNJ-7446"
      ]
    },
    {
      "nct_id": "NCT06816992",
      "overall_status": "RECRUITING",
      "phase": "PHASE1",
      "last_update_posted": "2025-03-20",
      "linked_assets": [
        "RYBREVANT"
      ]
    },
    {
      "nct_id": "NCT03767075",
      "overall_status": "RECRUITING",
      "phase": "PHASE2",
      "last_update_posted": "2024-04-25",
      "linked_assets": [
        "RYBREVANT"
      ]
    }
  ]
}